CD19 and non-Hodgkin lymphoma: Interestingly, results from another study that combined CD19 CAR-T cells with a PD-1 specific VHH domain of an anti-PD-1 nanobody to block PD-1 did not show improvement in NHL outcome and, on the contrary, it significantly reduced survival and diminished cytotoxicity [76].